MedDataX Logo

Comparative Treatment Study in Patients With Lower Ureteral Stones

NCT ID: NCT00397397

Last Updated: 2006-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We wish to determine the best treatment for expulsion of lower ureteral stones. Which of the three major treatment protocols is the best treatment of conservative management of ureteral stones?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include 60 patients with lower ureteral stones. The patients will be divided into three groups. The first group will be administered Alfuzosin (10 mg). The second group will be administered a combination of Alfuzosin (10 mg)and Rowatinex (Pinene 31%, Camphene 15%, Anetol 4%, Borneol 10%, Cineol 3%, Fenchenol 4%, Olive Oil 33%). The third group will be administered Rowatinex.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Calculi

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Urinary Calculi Rowatinex Alfuzosin Drug Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of lower ureter (urinary calculi) up to 8mm
* Must be able to swallow tablets

Exclusion Criteria

* Sensitivity to Alfuzosin and Rowatinex
* Pregnant and breastfeeding women
* Single kidney
* Obstructing stone
* Renal failure creatinine up to 1.8 mg/dl
* Patients using various alpha blockers
* Liver failure
* Fever higher than 38 C
* UTI
* Syncope or hypotension
* Patients treated with PDE5
* Patients treated with inhibitor CYP3A4
* Patients refusing participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hillel Yaffe Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriel Faragi

Role: PRINCIPAL_INVESTIGATOR

Urology Department, Hillel Yaffe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15/2006CTIL

Identifier Type: -

Identifier Source: org_study_id